Genome Grecision, a rare domestic provider specializing in comprehensive molecular diagnostics solutions for hematological diseases, announced the closing of roughly RMB 200 million in Series C financing. This round of financing was jointly led by Sunland Fund and Zhongguancun Co-Innovative Fund, with follow-on investments from Yinhe Yuanhui Investment and Guiyang Venture Capital, and continued support from existing shareholders Oriental Fortune Capital and Jiuren Capital.

CEC Capital Group served as the exclusive financial advisor for Genome Grecision in this transaction.

The proceeds from this financing will be used to further advance large-scale clinical trials and registration applications for the company's molecular diagnostic reagent products, rapidly replicate the overall solution in core tertiary hospitals, expand market coverage, and accelerate sales revenue growth to consolidate the company's leading position in the field of molecular diagnostics for hematological diseases.